Longeveron (LGVN) Cash & Equivalents (2021 - 2026)
Longeveron (LGVN) recorded quarterly Cash & Equivalents of $15.8 million in Q1 2026, up 238.08% quarter-over-quarter from $4.7 million in Q4 2025, and up 9.99% on a YoY basis from $14.3 million in Q1 2025.
Longeveron (LGVN) Cash & Equivalents (2021 - 2026) Analysis & Trends
Longeveron's Cash & Equivalents history runs 6 years deep, the most recent figure standing at $15.8 million for Q1 2026.
- In Q1 2026, Cash & Equivalents rose 9.99% year-over-year to $15.8 million; the TTM figure through Mar 2026 stood at $15.8 million (up 9.99% YoY), while the FY2025 annual figure was $4.7 million, down 75.76% from the prior year.
- Cash & Equivalents was $15.8 million for Q1 2026 at Longeveron, up from $4.7 million in the prior quarter.
- In the past five years, Cash & Equivalents ranged from a high of $22.8 million in Q3 2024 to a low of $1.9 million in Q1 2023.
- Historically, Cash & Equivalents has averaged $9.5 million across 5 years, with a median of $9.8 million in 2025.
- The sharpest annual moves came in 2024 and 2025: Cash & Equivalents soared 1059.13% in 2024, then tumbled 75.76% in 2025.
- A 5-year view of Cash & Equivalents shows it stood at $10.5 million in 2022, then sank by 52.88% to $4.9 million in 2023, then soared by 288.6% to $19.2 million in 2024, then sank by 75.76% to $4.7 million in 2025, then soared by 238.08% to $15.8 million in 2026.
- The last three Cash & Equivalents figures came in at $15.8 million (Q1 2026), $4.7 million (Q4 2025), and $9.2 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Equiv. (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | 32.30 Mn |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 1.91 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 286.70 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | 18.44 Mn |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | 2.77 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | 7.15 Mn |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 5.49 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | 558.94 Mn |
| 10 | Longeveron | 20.35 Bn | 20.33 Bn | 264,000.00 | 15.76 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 15.76 Mn |
| Dec 31, 2025 | 4.66 Mn |
| Sep 30, 2025 | 9.20 Mn |
| Jun 30, 2025 | 10.33 Mn |
| Mar 31, 2025 | 14.33 Mn |
| Dec 31, 2024 | 19.23 Mn |
| Sep 30, 2024 | 22.80 Mn |
| Jun 30, 2024 | 12.38 Mn |
| Mar 31, 2024 | 1.94 Mn |
| Dec 31, 2023 | 4.95 Mn |
| Sep 30, 2023 | 1.97 Mn |
| Jun 30, 2023 | 2.75 Mn |
| Mar 31, 2023 | 1.90 Mn |
| Dec 31, 2022 | 10.50 Mn |
| Dec 31, 2021 | 25.66 Mn |